ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1452

Handling of Missing Data, Protocol Violation and Performance of Intention-to-Treat Analysis in the Randomized Controlled Trials of Drug Therapy of Rheumatoid Arthritis

Fawad Aslam1, Karina Torralba2 and Nasim A. Khan3, 1Rheumatology, Mayo Clinic, Scottsdale, AZ, 2Division of Rheumatology, Department of Internal Medicine, Loma Linda University, Loma Linda, CA, 3Rheumatology, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Randomized trials and statistical methods

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster II: Prognostic Factors, Imaging and Miscellaneous Reports

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Intention-to-treat (ITT) method is recommended to analyze Randomized Controlled Trials (RCTs). It requires analyzing all participants per the assigned intervention group at randomization to prevent treatment effect estimation bias. In practice, RCTs have subjects with protocol deviations and/or missing outcomes. Incorrect analysis of these subjects may give biased results1,2. Single imputation methods like “last observation carried forward (LOCF)” are discouraged as they may bring bias, and don’t adjust for the uncertainty of imputation3. We studied the ITT principle application, protocol deviations and missing outcome data handling in RCTs of rheumatoid arthritis (RA) drug therapy.

Methods: MEDLINE and Cochrane Central Register of Controlled Trials database were searched to identify parallel-design, English language, original RCT reports of drug therapy for RA with clinical primary and efficacy outcome(s) published in 2002-3, 2006-7 and 2010-11. Two reviewers assessed each RCT for the primary outcome(s) analysis and handling of missing data.

Results: 134 RCTs were eligible and enrolled a median (interquartile range, IQR) of 160 (59-381) patients. A median (IQR) of 83 (70-90) % remained enrolled until trial completion. 92 (67%) RCTs lost >10% to follow-up for the primary outcome. 84 (62.7%) reported using ITT analysis, 10 (7.5%) reported modified ITT analysis, and 40 (29.9%) mentioned no such term. 63 (47%) RCTs actually performed true ITT analysis (analyzed all patients as randomized, although 7 RCTs had missing data with undefined approach to imputation). 32 (23.9%) performed a modified ITT analysis [percent analyzed: 97 (95-99)%] with exclusion of following categories: those without post-baseline assessment (17); no intervention received (12), and non-eligibility (1). 20 RCTs analyzed only those completing the trial per the study protocol [percent analyzed: 89 (86-97)%], while for 19 RCTs patients exclusion reason was unclear [percent analyzed: 91 (69-93)%]. Only 5 RCTs had all subjects complete the trials. Only 92 of the 129 (71%) RCTs with a missing final outcome described missing primary outcome handling which included: LOCF (51), non-responder assignment to those with missing data (29), calculation by interpolation (5). Only 2 RCTs did sensitivity analyses with different missing data assumptions. Experimental intervention efficacy could be assessed for 124 RCTs. The percentage of positive RCTs (statistical significance favoring experiment intervention) according to analytic method were: ITT (66%), modified ITT (87%), per-protocol (67%) and unclear (50%) [p = 0.056, Likelihood Ratio test].

Conclusion: A considerable variation in reporting and application of ITT principle in the RCTs exists. In about 30% RCTs, per-protocol or unclear analytic methods were used. Similar number of RCTs with missing data did not address handling of such data. Vast majority of RCTs used the non-recommended single imputation methods for missing data. A better description of subjects selected for final statistical analysis and approaches to deal with missing outcomes are needed.

References:

1. Hollis S. BMJ 1999;319:670-74

2. Sedgwick P. BMJ 2015;350:h681

3. Little RJ. N Engl J Med 2012;367(14):1355-60


Disclosure: F. Aslam, None; K. Torralba, None; N. A. Khan, None.

To cite this abstract in AMA style:

Aslam F, Torralba K, Khan NA. Handling of Missing Data, Protocol Violation and Performance of Intention-to-Treat Analysis in the Randomized Controlled Trials of Drug Therapy of Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/handling-of-missing-data-protocol-violation-and-performance-of-intention-to-treat-analysis-in-the-randomized-controlled-trials-of-drug-therapy-of-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/handling-of-missing-data-protocol-violation-and-performance-of-intention-to-treat-analysis-in-the-randomized-controlled-trials-of-drug-therapy-of-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology